<DOC>
	<DOC>NCT00681109</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of Topical Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior blepharitis.</brief_summary>
	<brief_title>Topical IL-1-Ra for Treatment of Posterior Blepharitis</brief_title>
	<detailed_description />
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>A diagnosis of posterior blepharitis A negative urine pregnancy test result for women of childbearing potential Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation Normal lid position and closure Ability to understand and provide informed consent to participate in this study Willingness to follow study instructions and likely to complete all required visits. History of StevensJohnson syndrome or ocular pemphigoid History of eyelid surgery Intraocular surgery or ocular laser surgery within 3 months History of microbial keratitis, including herpes Active ocular allergies Corneal epithelial defect &gt; 1mm2 Use of topical steroids or Restasis within the past 2 weeks Use of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month Use of isotretinoin (Accutane) within the past 6 months Have had any previous treatment with Anakinra (KineretÂ®) or any therapeutic agent targeted at IL1 blockade Pregnant or lactating women Signs of current infection, including fever and current treatment with antibiotics Liver, renal, or hematologic disease The use of any other investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>